Charles River Q2 2026 earnings: Organic growth returns as guidance rises

Charles River Laboratories (NYSE: CRL) reported Q2 2026 revenue of $1.00 billion, down 2.7% from $1.03 billion, while GAAP diluted EPS fell to a loss of $0.03 from earnings of $1.06 a year earlier. Organic revenue increased 0.1%, but non-GAAP EPS declined 3.2% as higher DSA study costs and corporate expenses pressured the underlying operating margin. Divestitures completed during the quarter also reduced reported revenue and generated a sizable GAAP loss.

Core earnings data

Reported revenue declined even as organic revenue returned to slight growth, reaching its highest growth rate since Q3 2023. Manufacturing Solutions and Discovery and Safety Assessment, or DSA, contributed to organic growth, while Research Models and Services, or RMS, remained a drag.

GAAP operating profitability improved because of CDMO-related effects and lower accelerated amortization, but a $63.7 million loss associated with the CDMO and Cell Solutions divestiture pushed net income into negative territory. On a non-GAAP basis, higher DSA study costs and unallocated corporate expenses reduced margins and earnings.

Business and segment performance

All three segments reported lower headline revenue, but their organic trends differed. DSA and Manufacturing generated modest organic growth, whereas RMS continued to contract.

DSA’s organic growth was driven by higher study volume in regulated safety assessment services. Management also reported the company’s highest net book-to-bill ratio in nearly four years, with demand improvement spanning global biopharmaceutical companies and small and midsized biotechnology clients. However, higher study-related direct costs prevented that demand improvement from translating into higher segment margins.

RMS was affected by lower North American revenue from small research models and research model services. Higher small-model revenue in China provided a partial offset, but lower volume and an unfavorable geographic mix reduced the segment’s non-GAAP margin.

Manufacturing’s reported decline primarily reflected the CDMO divestiture. Excluding portfolio and currency effects, organic revenue rose on higher Microbial Solutions sales, while the CDMO exit contributed to a substantially higher operating margin.

Divestitures lowered reported results but improved the margin mix

Charles River completed the divestitures of certain European Discovery Services sites and its CDMO and Cell Solutions businesses in May 2026. These transactions created a notable divergence among revenue, GAAP earnings and operating margins.

The removal of divested operations contributed to reported revenue declining despite slight organic growth. At the same time, the transactions produced a $63.7 million loss, equal to $1.40 per share, that was the principal reason GAAP EPS turned negative. Conversely, lower amortization and the effect of exiting CDMO operations helped lift GAAP operating margin and both GAAP and non-GAAP Manufacturing margins.

The result is that GAAP net income was heavily affected by transaction accounting, while non-GAAP results provided a clearer—but still weaker year-over-year—view of ongoing operating profitability.

Profitability and capital allocation

The 20.5% non-GAAP operating margin was 420 basis points higher sequentially but 160 basis points below Q2 2025. This contrast indicates that profitability recovered from the first quarter while remaining under pressure compared with the prior year, mainly because of DSA study costs and corporate expenses.

Non-GAAP EPS included a $0.19 benefit from investment gains associated with Charles River’s deferred compensation plan. Management expects that benefit to be largely offset by a higher tax rate over the full year, leaving a negligible net effect on 2026 non-GAAP EPS.

Charles River repurchased 0.6 million shares for $100 million during the quarter at an average price of $174. Year-to-date repurchases totaled 1.7 million shares and $300 million, leaving $700 million under the company’s existing authorization as of June 27, 2026.

2026 guidance

Charles River raised its reported and organic revenue outlook and increased non-GAAP EPS guidance. Management attributed the improvement primarily to better DSA demand and stronger-than-expected Manufacturing performance. GAAP EPS guidance moved in the opposite direction because of the divestiture-related loss and higher transaction and restructuring adjustments.

The wider separation between GAAP and non-GAAP EPS guidance reflects the increased transaction-related and restructuring adjustments rather than a reduction in management’s underlying operating outlook.

Management’s view

CEO Birgit Girshick characterized the demand improvement as broad-based and highlighted regulated testing, modernization and operating efficiency as strategic priorities. The company is seeking to deepen client relationships through initiatives including AI-enabled digital pathology, participation in Eli Lilly’s TuneLab platform and expanded next-generation sequencing services.

Management’s principal evidence of demand recovery was the nearly four-year high in net book-to-bill. Charles River is scheduled to provide a broader strategic update at its Investor Day on September 24, 2026.

Risks investors should monitor

• DSA costs could limit operating leverage. Bookings and study volume improved, but higher study-related direct costs reduced the segment’s non-GAAP margin from 27.4% to 25.6%.
• Bookings still need to convert into revenue. Companywide organic growth was only 0.1%, and the updated full-year organic growth range remains a modest 0% to 1% despite the improved demand indicators.
• RMS weakness remains unresolved. Lower North American small-model and research-services revenue, together with an unfavorable geographic mix, continued to pressure both growth and margin.
• Transaction and restructuring costs reduce GAAP visibility. The divestiture loss materially affected quarterly earnings, and guidance now incorporates higher acquisition, divestiture and efficiency-related adjustments.
• Investment gains are not expected to provide a full-year earnings benefit. Management expects a higher tax rate to largely offset the second-quarter deferred compensation investment gains.

Summary

Charles River’s Q2 2026 results showed an early improvement in demand, led by DSA bookings and organic growth in DSA and Manufacturing. That progress was obscured by divestitures, which reduced reported revenue and generated a GAAP loss, while underlying margins remained below the prior-year level because of study and corporate costs. The raised organic revenue and non-GAAP EPS guidance strengthens the operating outlook, but the next tests will be converting stronger bookings into revenue, restoring DSA margins and stabilizing RMS.